Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

Harbour Biomed Announces Dosing Of First Patient Of Two Phase I Trials For Next Generation Anti Ctla 4 Antibody Hbm4003

Facebook Comments

Leave a Reply

CommentLuv badge